Upcoming Events

Oncology RWE Workshop

Advancing Real-World Data to Generate Regulatory Grade Real-World Evidence in Oncology.

J.P. Morgan 42nd Annual Healthcare Conference

The state of innovation in a volatile market.

ISPOR EU 2023

HEOR at the nexus of policy and science.

Evidence Base Webinar (On-Demand)

SURF screening tool to determine suitability of using real-world evidence.

DIA RWE 2023

Explore new, innovative applications of RWE, and deliver cutting-edge insights to leverage this knowledge to advance healthcare decision-making. Various presentations and posters from Aetion.

ICPE 2023

The Global Home for the Science of Real-World Evidence. Various presentations and posters from Aetion.

DIA 2023

Catalyzing knowledge creation to ignite healthcare product development.

ISPOR US 2023

Impacting innovation, value, and healthcare decision-making. Various presentations and posters from Aetion.

J.P. Morgan 41st Annual Healthcare Conference

Deals and medical moonshots.

HLTH 2022

The overlooked medical research population: Pregnant people and their babies

DIA Real-World Evidence Conference

Leaping forward: The future of real-world evidence

DIA Real-World Evidence Conference

Year in review

DTx East 2022

Creating a novel data-driven approach for successful payer partnership outcomes

ICPE 2022

Various presentations

Assessing Re-Identification Risk Using Synthetic Data

Webinar

An Aetion + HealthVerity Webinar

Deep dive: Generating real-world evidence for pregnancy health

ISPOR 2022

Relevance of using international real-world data in regulatory and HTA decision making

ISPOR 2022

Lessons learned from health technology assessment pilot projects to assess real-world evidence’s usefulness in reassessments of effectiveness and value

ISPOR 2022

Getting real with real-world evidence for regulatory decision making: Where are we going?

ISPOR 2022

What is the preferred approach to US drug pricing reforms: International reference pricing or value based pricing?

Healthcare Unbound Summit

Breaking new grounds with RWE

Carolyn Magill

Duke-Margolis Real-World Evidence Collaborative

The state of real-world evidence policy

Jeremy Rassen, Sc.D.

A HealthVerity + Aetion Webinar

Advancing real-world evidence generation for pregnancy health

RWE4Decisions

Roundtable discussion: Data sources & data quality

Webinar

Making sense of FDA’s 2021 real-world evidence guidance: Part 2: Assessing registry data

SCOPE Summit

Bridging the RCT and RWE universes with calibration trials

Sebastian Schneeweiss, M.D., Sc.D.

Endpoints at JPM 2022

Commercializing novel disease-modifying categories

MEDAAX

RWE and regulatory decisions

Webinar

Making sense of FDA’s 2021 real-world evidence guidance

Partnering for Patients Forum

Is digital health a bridge to health equity and representation?

Innovaccer Webinar

How digital ecosystems can help deliver value of medical innovations to providers and patients and drive benefits across health care

Virtual ISPOR Europe 2021

Who and what are we missing in real-world data? How do we improve the capture of social determinants of health?

Virtual ISPOR Europe 2021

Who can we see in RWD? Assessing capture of demographic data across multiple countries

2021 ISPOR Virtual Short Courses

Use of propensity scores in observational studies of treatment effects

Jeremy Rassen, Sc.D.

DIA Real-World Evidence Conference

Year in review

AMCP Nexus 2021

Characteristics and treatment patterns among patients with epilepsy initiating antiseizure drug therapy, 2016-2019: Analyses from a US claims database

AMCP Nexus 2021

Comparison of healthcare resource utilization and cost among newer antiseizure drugs during titration: An analysis from a US claims database

AMCP Nexus 2021

Non-persistence among patients with psoriasis on interleukin (IL)-17 inhibitor therapy: A US claims analysis

AMCP Nexus 2021

The economic burden of non-persistence among patients with psoriasis on interleukin (IL)-17 inhibitor therapy: A US claims analysis

HLTH

Drug discovery’s AI engine

Carolyn Magill

DIA Japan Lifestyle Management Workshop

Should we use RWD or not use it? Lifecycle management considered by Fit for Purpose

Sebastian Schneeweiss, M.D., Sc.D.

2021 ISPOR Virtual Short Courses

Developing decision-grade real-world evidence

ICPE All Access 2021

Various presentations

Monsenso Webinar

Patient voice in RWE: Advances, opportunities, and action

Boston TBA 2021 Annual Symposium

Real-world evidence: Trends and application of real-world data in drug development and safety

DIA 2021 Virtual Global Annual Meeting

Update on FDA’s vision on real-world evidence: Current FDA projects

Sebastian Schneeweiss, M.D., Sc.D.

BIO Clinical Trial and Diversity Summit

The role of technology and data in building a sustainable, expanded and inclusive clinical trial network ecosystem

Carolyn Magill

Proventa International Oncology Strategy Meeting Online 2021

Keynote presentation

Nicolle Gatto, Ph.D., M.P.H.

BIO Digital Convention

RWE advancements towards COVID-19 therapeutics

Carolyn Magill

2021 AcademyHealth Annual Research Meeting

The changing nature of evidence

Carolyn Magill

DIA Future of Evidence and Smart Health Conference

Unwrapping RCT DUPLICATE

Jeremy Rassen, Sc.D.

DIA Future of Evidence and Smart Health Conference

Innovative approaches to integrated evidence

Databricks Data + AI Summit 2021

Health and life sciences industry forum

Carolyn Magill

Global Strategic R&D Partnerships and Innovative Collaboration Virtual Event

Using global real-world data & evidence to support R&D via Partnership models

National Academies Workshop: Building Data Capacity for Patient Centered Outcomes Research

Perspectives on advances in RWE methods

United States of Care Event Series

Bringing the perspectives of people to CMMI: Real-world models and recommendations for the CMS Innovation Center

Carolyn Magill

JHU-FDA CERSI Webinar: Advancing COVID-19 Regulatory Science Using Clinical Informatics

Advancing COVID-19 data science and bioinformatic methods

Jeremy Rassen, Sc.D.

Virtual ISPOR 2021

Should we be talking “embedded” rather than “pragmatic” for real-world clinical trials?

Danish Medicines Agency DAC Master Class

Pharmacovigilance 2.0 – real world signal generation

Jeremy Rassen, Sc.D. Sebastian Schneeweiss, M.D., Sc.D.

Social Insurance Innovation Forum: Data and Social Security - Opportunities for Health Care and Science

Supply systems and improvements

Sebastian Schneeweiss, M.D., Sc.D.

HTAi Real-World Evidence and Artificial Intelligence Interest Group

Compare and contrast RWE guidelines across decision-makers including HTAs

4th Annual MarketsandMarkets Real-World Data, Life Sciences Analytics, and Market Access Virtual Conference

RWE for demonstrating drug effectiveness

ISPE Mid-Year Virtual Meeting

Rise of the machines: Big data analytics and machine learning in pharmacoepidemiology

Jeremy Rassen, Sc.D.

University of Rochester's Center for Health + Technology

CHeT Talk: Fireside chat

Carolyn Magill

Flare Capital Partners Expert Roundtable Series

Building world-class teams

Carolyn Magill

Informa webinar

How leading-edge R&D teams are using RWE

The 18th Annual Montgomery Summit 2021

Vertical software

Carolyn Magill

Scope Summit

RWD analytics, collaboration, historical data: Collaborating to generate fit-for-use RWE post COVID-19

Digital Medicine Week

Evidence Con: Taking it to practice

2021 Health Datapalooza and National Health Policy Conference

Novel ways of generating and returning evidence to the patient

Julie Schiffman

Duke-Margolis virtual workshop

Evaluating RWE from observational studies in regulatory decision-making: Lessons learned from trial replication analyses

Sebastian Schneeweiss, M.D., Sc.D.

FDAnews Webinar

FDA under the Biden Administration: What’s to come and what it will mean

Lowell Schiller, J.D.

7th Annual LSX World Congress

Optimizing real-world evidence and real-world data

Carolyn Magill

Society for Epidemiologic Research 2020 Virtual Annual Conference

Confounding control for estimating causal effects: Looking under the hood

Society for Epidemiologic Research 2020 Virtual Annual Meeting

Better targeting of target populations: Methods for health disparities research

Society for Epidemiologic Research 2020 Virtual Annual Meeting

A neural-network driven longitudinal propensity score for evaluation of drug treatment effects

ICPE All Access

Visual space: Using visualization in pharmacoepidemiology to design and disseminate valid real-world evidence in a structured framework

Jeremy Rassen, Sc.D.

DIA Real-World Evidence Conference

What will the generation and application of RWE look like in 2030?

Jeremy Rassen, Sc.D.

Crosstalks Online Workshop

Real-world data and evidence: Challenges for stakeholders aiming at a value-based health care system

ACDRS Webinar Series

Role of real-world evidence in regulatory decision-making before, during, and after COVID

ICPE All Access

Applied sensitivity analysis

Sebastian Schneeweiss, M.D., Sc.D. Jeremy Rassen, Sc.D.

Virtual ISPOR Europe 2020

Comparison of external control arm critiques in regulatory and health technology assessment oncology submissions

ICPE All Access

Comparative effectiveness research

Sebastian Schneeweiss, M.D., Sc.D.

DIA Real-World Evidence Conference

The selection and use of external comparators for expedited drug development

Jeremy Rassen, Sc.D.

ICPE All Access

Advanced pharmacoepidemiology: Pharmacoepidemiologic methods used in COVID research

Jeremy Rassen, Sc.D.

Fortune Global Forum

What it takes: Thriving in the data age

Carolyn Magill

3rd Annual MarketsandMarkets RWD, Life Sciences Analytics, and Market Access Virtual Conference

Regulatory and HTA decision-making: Latest precedent and what’s ahead

ICPE All Access

Lessons learned from replicating clinical trials with real-world data

Sebastian Schneeweiss, M.D., Sc.D.

ICPE All Access

Propensity scores in pharmacoepidemiology

Jeremy Rassen, Sc.D.

ICPE All Access

Machine learning to optimize and automate confounding control in studies using high-dimensional health care data

Sebastian Schneeweiss, M.D., Sc.D.

World Pharma Pricing and Market Access Congress

RWE for regulatory and HTA decision-making: latest precedent and what’s ahead

Morgan Stanley Virtual Global Healthcare Conference

Fireside chat

Carolyn Magill

Virtual ISPOR Asia Pacific 2020

Access to personalized medicine: Challenges from single arm studies

Jeremy Rassen, Sc.D.

Webinar with McDermott Will & Emery LLP

Evolving opportunities and challenges for real-world evidence and data-powered solutions

Carolyn Magill

HTAi 2020 Virtual Annual Meeting

What does good look like? Evaluating decision-grade RWE

PCMG Live

COVID-19: Forces innovation! Speeding up the pace of change

Jeremy Rassen, Sc.D.

Webinar with HealthVerity

RWE and real-time insights: how to advance regulatory and commercial strategy in the COVID-19 era

Jeremy Rassen, Sc.D.

HTAi Annual Meeting 2020

What does good look like? Evaluating decision-grade real-world evidence

Jeremy Rassen, Sc.D.

DIA 2020 Virtual Global Annual Meeting

Combining multiple real-world data sources to maximize value

Jeremy Rassen, Sc.D.

BIO Digital 2020

Financing transformative therapies: Cross-sector perspective on value and payment

HealthEconomics.com webinar

How to build a leading-practice RWE program to inform innovative drug contracting and market access

Carolyn Magill

DIA Biostatistics Industry and Regulator Forum

A community of networks: Creating and leveraging a network of distributed data supporting medical product development

Jeremy Rassen, Sc.D.

Virtual ISPOR 2020

RWE guidance and frameworks: What elements are necessary to promote quality, transparency, and validity in real-world evidence

ISPOR 2020

Developing decision-grade real-world evidence

Jeremy Rassen, Sc.D. Sebastian Schneeweiss, M.D., Sc.D.

Informa webinar

Real-world evidence for regulatory decision-making

Jeremy Rassen, Sc.D. Sebastian Schneeweiss, M.D., Sc.D.

DIA Biostatistics Industry and Regulator Forum

A community of networks, creating, and leveraging a network of distributed data supporting medical product development

Jeremy Rassen, Sc.D.

WuXi Online Forum II on COVID-19

Harnessing our collective power

Carolyn Magill

eyeforpharma Barcelona Virtual 2020

Generate RWE pre-approval to inform regulatory decisions and expand access

Carolyn Magill

MIT Sloan Healthcare and BioInnovations Conference

Innovation showcase presentation

RWE Leaders Forum

Guest speaker session

Carolyn Magill

BIO CEO & Investor Conference

Commercialization strategies for communicating evidence of a therapy’s value

Carolyn Magill

HBS 17th Annual Health Care Conference

Lunch roundtable

J.P. Morgan 38th Healthcare Conference

WuXi global forum: “The shifting paradigm: From sick care to health care”

Carolyn Magill

W2O's 6th Annual Digital Health Luncheon at J.P. Morgan

Healthcare’s use of data and new data sources

Carolyn Magill

HIMSS & Health 2.0 Japan 2019

Keynote: Using real-world evidence to answer critical questions in health care

Jeremy Rassen, Sc.D.

Digital Healthcare Innovation Summit

Building a strong case with real-world evidence

Carolyn Magill

Longwood Annual Healthcare Leaders Meeting

Getting to drug approval

Carolyn Magill

16th Global Cardiovascular Clinical Trialists Forum

Real-world data to predict randomized trial results before they’re done: The RCT DUPLICATE initiative

eyeforpharma Webinar

Let’s talk about value: Use RWE to determine drug price and performance

Carolyn Magill

United States of Care 2019

Next generation challenges and opportunities in health care

Carolyn Magill

DIA Real World Evidence Conference

What’s next: Real-world evidence in the development and access of novel therapeutics

Jeremy Rassen, Sc.D.

Friends of Cancer Research Annual Meeting

Characterizing the use of external controls for augmenting randomized control arms and confirming benefit

Jeremy Rassen, Sc.D.

ISPOR Europe 2019

Big healthcare data — Endless opportunities for research and learning

Jeremy Rassen, Sc.D.

ISPOR Europe 2019

Are value assessment frameworks using RWE? A review of NICE and ICER psoriasis assessments

ISPOR Europe 2019

Transparency in RWE — Time for a unified approach

Sebastian Schneeweiss, M.D., Sc.D.

ISPOR Europe 2019

Themes in the design of pharmaceutical value-based contracts in the United States and Europe

ISPOR Europe 2019

Are we there yet? Using RWD for regulatory-grade external control arms

Jeremy Rassen, Sc.D.

ISPOR Europe 2019

Use of propensity scores in observational studies of treatment effects

Jeremy Rassen, Sc.D.

AMCP Nexus 2019

Using real-world evidence to design value-based contracts for the real world

HLTH - The Future of Healthcare

The 7 things smart companies do to close the gender gap

Carolyn Magill

HLTH - The Future of Healthcare

Real-world evidence for value-based care

Carolyn Magill

2nd Annual MarketsandMarkets Real-World Data and Life Science Analytics Congress

Panel discussion: Pros & cons of real-world evidence framework by FDA. Perspective from different stakeholders — providers & payers

2019 Wharton Health Care Conference on Artificial Intelligence

Real-world evidence case study

Carolyn Magill

Connected Health Conference

How real-world evidence will facilitate the shift toward value-based care

ISPOR Summit 2019

Transparency in RWE — Time for a unified approach

Sebastian Schneeweiss, M.D., Sc.D.

Duke-Margolis: Developing Real-World Data and Evidence to Support Regulatory Decision-Making

Methodological and analytical considerations for observational studies

Sebastian Schneeweiss, M.D., Sc.D.

Future of Health

Digital Health 150

Jeremy Rassen, Sc.D.

Friends of Cancer Research 8th Annual Blueprint for Breakthrough Forum

The future of real-world evidence: Informing regulatory and payer decisions

Jeremy Rassen, Sc.D.

IMPACCT: RWE

Real-world evidence to support regulatory submissions

Sebastian Schneeweiss, M.D., Sc.D.

Health 2.0

The keys to outcome and evidence-based care

Carolyn Magill

35th ICPE

Causal inference in pharmacoepidemiology

Sebastian Schneeweiss, M.D., Sc.D.

35th ICPE

Where should I submit my paper? Applying machine learning to enhance communication of medical research

Jeremy Rassen, Sc.D.

35th ICPE

Inferring mortality in claims data

35th ICPE

Poster, podium, and symposia presentations

Jeremy Rassen, Sc.D. Sebastian Schneeweiss, M.D., Sc.D.

35th ICPE

Reproducibility of a population-based cohort study characterizing newly diagnosed multiple myeloma patients in the UK using an EHR database

35th ICPE

Incidence of Fournier’s gangrene in type 2 diabetic patients using second-line antidiabetic drugs

35th ICPE

The ascension of real-world evidence: Can (and should) we establish thresholds for validity?

Sebastian Schneeweiss, M.D., Sc.D.

35th ICPE

What does replicable and robust non-randomized database evidence look like?

Jeremy Rassen, Sc.D.

35th ICPE

Clinical outcomes in patients with type 2 diabetes newly initiating SGLT2 or DPP4 inhibitors

35th ICPE

Propensity scores in pharmacoepidemiology

Jeremy Rassen, Sc.D.

35th ICPE

Applied sensitivity analyses in pharmacoepidemiology database studies

Jeremy Rassen, Sc.D.

eyeforpharma Webinar

The real-world evidence regulatory evolution: How to use RWE to augment RCTs and advance the drug development paradigm

Jeremy Rassen, Sc.D. Sebastian Schneeweiss, M.D., Sc.D.

DIA Global Annual Meeting

Use of real-world evidence to support regulatory decision-making: First-year findings from the RCT-DUPLICATE project

Jeremy Rassen, Sc.D.

DIA Global Annual Meeting

Using real-world data to develop a safety monitoring program and ensure pre- and post-market continuity

Jeremy Rassen, Sc.D.

5th Annual d.health Summit: Aging Americans Innovation Conference

Facilitated discussion

Carolyn Magill

American Diabetes Association

RWD analyses for regulatory decision-making

Sebastian Schneeweiss, M.D., Sc.D.

BIO 2019

Real-world data external controls panel

Jeremy Rassen, Sc.D.

ISPOR 2019

Quantifying the opportunity to reduce total cost of care through targeted medication prioritization and adherence improvement in diabetes

Jeremy Rassen, Sc.D. Sebastian Schneeweiss, M.D., Sc.D.

ISPOR 2019

Replicable and robust database evidence: What does it look like?

Jeremy Rassen, Sc.D.

ISPOR 2019

Replication of randomized controlled trials using real-world data: What does good look like?

Sebastian Schneeweiss, M.D., Sc.D.

ISPOR 2019

De-Risking Risk Sharing: Enabling Payer-Pharma Interactions and Value-based Contracting with RWE

Jeremy Rassen, Sc.D. Sebastian Schneeweiss, M.D., Sc.D.

ISPOR 2019

Use of propensity scores in observational studies of treatment effects

Jeremy Rassen, Sc.D.

2019 Blue Cross Blue Shield National Summit

Applying rapid-cycle analytics of real-wolrd data to reduce medical costs and improve outcomes among high-risk members: case studies in diabetes and inflammatory bowel disease

12th Annual FDA/AdvaMed Medical Devices & Diagnostics Statistical Issues Conference

An approach for incorporating real-world evidence into regulatory decision-making

eyeforpharma Philadelphia

Panel: A strategic cross-functional approach to evidence generation

Health Evolution Summit

Corporate Venture Group panel

Carolyn Magill

Danish Epidemiological Society Spring Meeting 2019

Automated data adaptive analytics for electronic healthcare data to study causal treatment effects

Sebastian Schneeweiss, M.D., Sc.D.

ISPE's 2019 Mid-Year Meeting

Scientific perspectives on biologic and biosimilar use

Sebastian Schneeweiss, M.D., Sc.D.

FORTUNE Brainstorm Health 2019

Lunch session

Carolyn Magill

Healthcare Costs Innovation Summit

The value-based care movement

Carolyn Magill

Harvard-MIT CRS Regulatory Science Symposium 2019

Real-world evidence sessions

2019 Health Datapalooza

Rapid fire: Real world evidence

Carolyn Magill

AMCP Managed Care & Specialty Pharmacy Annual Meeting

Using rapid-cycle analytics of real-world data to manage high risk, high cost patients

International Society for Pharmacoepidemiology (ISPE) Webinar

Visual pharmacoepidemiology

Jeremy Rassen, Sc.D.

Pharmaceutical Executive Webinar

Using real-world evidence for U.S. regulatory decision-making: What pharma needs to know

Carolyn Magill Sebastian Schneeweiss, M.D., Sc.D.

RWE Europe at eyeforpharma Barcelona

Understand the acceptability of RWE across global regulatory decision-making

Jeremy Rassen, Sc.D.

DIA Europe 2019

Confidence in real world data

Sebastian Schneeweiss, M.D., Sc.D.

National Health Policy Conference

Future directions in regulatory policy: the role of real-world evidence

Jeremy Rassen, Sc.D.

DIA's Pharmacovigilance and Risk Management Strategies Conference

When and how can RWD analyses support regulator decision making

Sebastian Schneeweiss, M.D., Sc.D.

Duke-Margolis Center for Health Policy

Unpacking real-world data curation: Principles and best practices to support transparency and quality

Jeremy Rassen, Sc.D.

International Society for Pharmacoepidemiology (ISPE) Webinar

A decade of experience with high-dimensional propensity scores

Sebastian Schneeweiss, M.D., Sc.D.

Symposium on Accessibility and Impact of High Value Medicines

Evidences of access impact: Conclusions from the satellite workshop

Sebastian Schneeweiss, M.D., Sc.D.

Symposium on Accessibility and Impact of High Value Medicines

How can observational studies reproduce causality assessment

Sebastian Schneeweiss, M.D., Sc.D.

37th Annual J.P. Morgan Healthcare Conference

Digital health panel

Carolyn Magill

U.S. News Healthcare of Tomorrow 2018

Next steps for value-based care

Carolyn Magill

ISPOR Europe 2018

Addressing challenges to open science: Data sharing, replication, and robustness of evidence from real world data

Sebastian Schneeweiss, M.D., Sc.D.

ISPOR Europe 2018

Use of propensity scores in observational studies of treatment effects

Jeremy Rassen, Sc.D.

8th Annual eyeforpharma Value Summit

The future of pharma requires a value shift

CNODES Semi-Annual Meeting

Pharmacoepidemiology for regulatory decision making and the importance of analytic platforms

Sebastian Schneeweiss, M.D., Sc.D.

Real World Evidence Conference

Non-interventional studies: Study design considerations and current applications

Sebastian Schneeweiss, M.D., Sc.D.

ACPE 2018

Real world evidence or clinical trials? Which should I believe?

Jeremy Rassen, Sc.D.

ACPE 2018

Advanced analytic methods in pharmacoepidemiology

Jeremy Rassen, Sc.D.

Real-World Insights & Life Science Analytics Congress

Effective use of real-world data analytics across the life cycle: Data, analytics, people, organizations

Sebastian Schneeweiss, M.D., Sc.D.

Real-World Insights & Life Science Analytics Congress

Bringing two worlds together

20 years of DoPE

From better prediction to transparent outcome evaluation with advanced analytics

Jeremy Rassen, Sc.D.

20 years of DoPE

Real-world data in the peri-approval space

Sebastian Schneeweiss, M.D., Sc.D.

BIO Investor Forum

How real-world evidence can improve clinical trial productivity

Jeremy Rassen, Sc.D.

Fortune Global Forum 2018

Big data: Transforming global health care

Carolyn Magill

Health 2.0

One size does not fit all: Advances in precision health and medicine

University of Bordeaux

Data-adaptive methods for causal inference, automation, and the rise of analytic platforms in pharmacoepidemiology

Sebastian Schneeweiss, M.D., Sc.D.

34th ICPE

Applied sensitivity analyses in pharmacoepidemiology database studies

Sebastian Schneeweiss, M.D., Sc.D.

34th ICPE

Propensity scores in pharmacoepidemiology

Jeremy Rassen, Sc.D.

34th ICPE

Advanced topics in PE: Healthcare database analyses for regulatory decision making

Sebastian Schneeweiss, M.D., Sc.D.

34th ICPE

Comparative effectiveness research: Real-world evidence in health technology assessment

Sebastian Schneeweiss, M.D., Sc.D.

Karolinska Institutet

Real world data analyses for regulatory decision making – a global opportunity

Sebastian Schneeweiss, M.D., Sc.D.

Drug Safety Research Unit

Big data for pharmacovigilance

Jeremy Rassen, Sc.D.

d.health Summit

Leveraging real-world data to optimize value-based care & improve health outcomes

Carolyn Magill

ISPOR 2018

Use of propensity scores in observational studies of treatment effects

Jeremy Rassen, Sc.D.

2018 Accelerating Anticancer Agent Development and Validation (AAADV) Workshop

Examination of supplemental indication in cardiology using real-world data

Sebastian Schneeweiss, M.D., Sc.D.

Health Datapalooza

Taming the life sciences data beast

Carolyn Magill

Duke-Margolis Center for Health Policy

Workshop on real-world data quality

Sebastian Schneeweiss, M.D., Sc.D.

Duke-Margolis Center for Health Policy

Workshop on the regulatory applications of observational studies

Sebastian Schneeweiss, M.D., Sc.D.

ASCPT 2018

Using complex healthcare databases to evaluate the safety and effectiveness of newly marketed medications

Sebastian Schneeweiss, M.D., Sc.D.

The National Academies of Sciences, Engineering, and Medicine Workshop

Healthcare database analyses of medical products for regulatory decision-making

Sebastian Schneeweiss, M.D., Sc.D.

National Institutes of Health

Gadolinium Deposition: What We Know and Don’t Know

Sebastian Schneeweiss, M.D., Sc.D.

American Journal of Law & Medicine Symposium

Developing Real World Evidence Fit for Regulatory Decision Making

Sebastian Schneeweiss, M.D., Sc.D.

CFDA China Center for Food & Drug International Exchange Conference

Transforming big, real-world data for decision-making about medical treatments

Jeremy Rassen, Sc.D.

NEWDIGS​ at MIT

Driving Value for Patients from Real World Evidence: Snapshots of Evolving Ecosystems

Sebastian Schneeweiss, M.D., Sc.D.

EMA 2017

Common Data Models for Regulatory Decision Making

Sebastian Schneeweiss, M.D., Sc.D.

World Economic Forum

Value in healthcare

Sebastian Schneeweiss, M.D., Sc.D.

ISOP Annual Meeting

Use of big data in drug safety applications

Jeremy Rassen, Sc.D.

Real-World Analytics Summit

Panel Discussion: The Uptake of Real-World Data Analytics

Sebastian Schneeweiss, M.D., Sc.D.

International Society of Biopharmaceutical Statistics Annual Meeting

Generating Real World Evidence that is Fit For Decision Making

Sebastian Schneeweiss, M.D., Sc.D.

ISPE Annual Meeting

ISPE: Course on Propensity Scores

Jeremy Rassen, Sc.D.

Joint Statistical Meeting

Real world evidence to support accelerated approval processes

Sebastian Schneeweiss, M.D., Sc.D.

FDA Science Forum

Categorization of COVID-19 severity to determine mortality risk

FDA Science Forum

Temporal trends in medication utilization among hospitalized COVID-19 patients in the United States

ICPE 2023

ICPE 2023